Recent research data and supporting animal studies have shown that acute kidney injury (AKI) can eventually lead to chronic kidney disease (CKD). Moreover, the frequency of kidney transplants as result of CKD have been increasing daily. Various renal disorders result in end stage renal failure (ESRF) including glomerulonephritis, hypertensive nephrosclerosis and diabetic nephropathy (Levey and Coresh 2012) . Chronic kidney disease involves conditions such as glomerulonephritis, glomerular endothelial cell injuries accompanies mesangial alterations or extracapillary lesions. To retrieve the glomerular endothelial cells in these models, angiogenesis stimulation is required to promote glomerular endothelial repair in association with accelerated resolution of nephritic alterations. The level of angiogenic signal should be adjusted according to the type and the stage of disease, to avoid an imbalance of pro / antigrowth and promotion of other pathologic condition as result of excessive angiogenesis (Goligorsky 2015; Levey and Coresh 2012) . The development of new blood vessels, termed angiogenesis is responsible for several physiological and pathological events such as tumor growth and metastasis, proliferative retinopathy, rheumatoid arthritis, psoriasis and neointimal formation (Risau 1997 ). This process is controlled by pro and antigrowth factors and it is directly associated with the development of renal failure. Consequently, balanced ratios of these factors control severe renal conditions (Carmeliet 2003) The deregulated expression of factorsinhibitors ends in pathological conditions, like inflammation. Although findings about the biological role of angiogenesis factors in CKD are relatively limited, therapeutic effects have been reported for angiogenesis factors in experimental diabetic nephropathy models. Angiogenesis inhibitors exhibit therapeutic effects on diabetic nephropathy by anti-angiogenic and anti-inflammatory mechanisms. These effects highlight the importance of a tight regulation of angiogenic factors and inhibitors (Tanaka and Nangaku 2013) . e role of VEGF is unknown in normal kidney physiology, however VEGF and its receptor are up-regulated in type 1 and 2 diabetes. Also inhibition of VEGF and VEGFR expression ameliorate diabetic kidney condition (Schrijvers et al. 2004) . VEGF plays an important role in maintaining the glomerular capillary struc-
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An insight into chronic kidney disease (CKD) through an unbalanced angiogenesis ture, and in the repair process following injuries to the glomerular endothelial cells and peritubular capillaries (PTC). Physiological levels of VEGF-A are also required for maintenance of glomerular ltration (Khamaisi et al. 2003) .
Angiopoietins
Reduction in circulating levels of Ang-1, and elevation of Ang-2 levels in patients with CKD displays moderate to severe renal dysfunction . In a mouse model of folic acid-induced nephrotoxicity, Ang-1 was detected in renal arterial walls and in injured cortical distal tubules. In a mouse anti-glomerulonephritis model, the glomerular level of Ang-1 was reduced and Ang-2 was increased, in association with glomerular endothelial cell apoptosis. In a mouse model of unilateral ureteral obstruction, reduction in renal Ang-1 level was observed.
is research data suggest that Ang-1 supplementation can have variable outcomes on renal injuries, depending on the disease model (Futrakul and Futrakul 2011; Woolf et al. 2009 ).
Other angiogenic factors
In a mouse model of ischemia-reperfusion injury ( in human diabetic nephropathy, in addition to its potent anti-tumor e ect (Chen et al. 2012 ).
Angiostatin
Angiostatin is a proteolytic fragment of plasminogen and a potent angiogenic inhibitor. Previous studies have shown that angiostatin inhibits retinal neovascularization and reduces retinal vascular permeability in diabetic retinopathy (Chen et al. 2012 ).
e potential involvement of angiostatin in diabetic nephropathy using an STZ-induced type 1 diabetes rat model was examined.
Angiostatin levels were dramatically decreased in the kidneys of diabetic control rats, and adenovirus-mediated delivery of angiostatin signi cantly ameliorated albuminuria and glomerular hypertrophy in diabetic rats. Inhibitory e ects of Angiostatin treatment on VEGF-A and TGF-β1 in diabetic kidneys were also observed. Angiostatin produced direct e ects on mesangial cells and endothelial cells, as well as therapeutic e ects on diabetic nephropathy (Boor and Floege 2011; Zhang et al. 2006 ).
Vasohibin-1
Vasohibin (VASH)-1, an endogenous angiogenesis inhibitor, was identi ed in a microarray analysis, assessing genes upregulated by VEGF-A in endothelial cells. VASH-1 serves as an endothelial cell-derived negative feedback regulator of angiogenesis, and its therapeutic e cacies on tumor growth, atherosclerosis and proliferative retinopathy models have been reported. e studies on STZ-diabetic rats suggest therapeutic potential for VASH-1 in treating early diabetic nephropathy thought to be mediated via gl-omerular endothelial and mesangial cells (Maeshima and Makino 2010) .
Conclusion
e nding revealed that advances study on the involvement of angiogenic and antiangiogenic factors in CKD and potential experimental approaches using angiogenesis inhibitors to treat CKD, including diabetic nephropathy. Based on the mechanistic insight into the involvement of angiogenesis in CKD, the use of novel therapeutic reagents in patients with CKD in clinical practice is expected in the near future, leading to the eventual decrease in the number of patients developing ESRD.
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